---
document_datetime: 2023-09-21 18:39:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/levviax-epar-procedural-steps-taken-authorisation_en.pdf
document_name: levviax-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.699853
conversion_datetime: 2025-12-26 19:48:21.766922
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

<!-- image -->

Medicinal Product no longer authorised 1. Submission of the dossier The applicant,  Hoechst  Marion  Roussel  submitted  on  24  March  2000  an  application  for  Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for Ketek/Levviax, through the centralised procedure. After agreement by the CPMP on 13 April 2000, this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC) 2309/93 of 22 July 1993 as amended.  On 12 February 2001, the applicant informed the EMEA about the  merger of Hoechst Marion Roussel into Aventis Pharma S.A. This merger is effective since 31 December 2000. The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr. P. Nilsson Co-Rapporteur: Prof C. Sampaio Scientific Advice: The Applicant received Scientific Advice from the CPMP on 22 October 1998 and 17 December 1998 (follow-up).  The Scientific Advice pertained to Part II of the dossier. Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 14 April 2000. · The Rapporteur's first Assessment Report was circulated to all CPMP members on 22 June 2000 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 26 June 2000 (Annex 2). · During the meeting 25-27 July 2000 the CPMP adopted the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 26 July 2000 (Annex 3). · The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  15 January 2001. · The summary report of the inspection carried out on 16-19 January 2001 at the manufacturing site  in  Kansas  City  US  has  been  issued  by  the  Ministero  della  Sanitá,  Italy  and  the  Medical Products Agency, Sweden (Annex 4) · The Rapporteur circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 5 March 2001 (Annex 5) · During the meeting on  27-29 March 2001 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee  issued  a  positive  opinion  for  granting  a Marketing Authorisations for Ketek and Levviax to Aventis Pharma S.A. on 29 March 2001.